Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche

Arnob Banerjee(Johnson & Johnson (United States)), Steven L. Reiner(Columbia University Irving Medical Center), Scott M. Gordon(Cancer Research Institute of the Slovak Academy of Sciences), E. John Wherry(Parker Institute for Cancer Immunotherapy), Erin C. Mooney(Virginia Commonwealth University), Michael Paley, Tulia Lindsten(Cancer Research Institute of the Slovak Academy of Sciences), Andrew M. Intlekofer(Memorial Sloan Kettering Cancer Center)
The Journal of Immunology
October 9, 2010
10.4049/jimmunol.1002042
Cited by 417

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
|Science|2021|932
T cell responses in patients with COVID-19
|Nature reviews. Immunology|2020|873